查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1387324

全球抗生素抗药性市场：趋势、预测和竞争分析（~2030 年）

Antibiotic Resistance Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

抗生素抗药性趋势和预测

预计到2030年，全球抗生素抗药性市场规模将达到约122亿美元，2024年至2030年年复合成长率为5.9%。该市场的主要驱动因素是抗生素的日益普及以及政府和非政府组织越来越多地参与新治疗方法的开发。全球抗生素抗药性市场前景广阔，医院药局、零售药局、线上药局市场蕴藏商机。

抗生素抗药性市场洞察

Lucintel 预计，由于有强大的产品开发平臺，cUTI（复杂尿道感染）在预测期内仍将是最大的细分市场。

医院药剂师将继续成为该市场中最大的部分，因为他们在监督药物处方、追踪抗药性模式、提供教育和确保药物安全方面发挥关键作用。

由于该地区政府计划和强制保险政策的增加，北美在预测期内将继续成为最大的地区。

本报告回答了 11 个关键问题：

  • Q.1. 细分市场中最有前途和高成长的机会是什么？
  • Q.2.哪个细分市场将以更快的速度成长？为什么？
  • Q.3.您认为哪些地区未来会出现更快的成长？为什么？
  • Q.4. 影响市场动态的主要因素有哪些？市场的主要挑战和商业风险是什么？
  • Q.5. 这个市场的商业风险和竞争威胁是什么？
  • Q.6.这个市场有哪些新趋势？为什么？
  • Q.7.市场客户需求有何改变？
  • Q.8. 该市场有哪些新发展以及哪些公司处于领先地位？
  • Q.9.这个市场的主要企业有哪些？主要企业采取哪些策略配合措施来发展业务？
  • Q.10. 该市场上的竞争产品有哪些？由于材料或产品替代而导致市场占有率下降的威胁有多大？
  • Q.11.过去年度发生了哪些併购事件，对产业产生了哪些影响？

目录

第1章执行摘要

第2章全球抗生素抗药性市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第3章2018-2030年市场趋势与预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球抗生素抗药性市场趋势（2018-2023）与预测（2024-2030）
  • 全球抗生素抗药性市场：依疾病分类
    • cUTI (Complicated Urinary Tract Infections)
    • CDI (Clostridioides difficile Infection)
    • ABSSSI (Acute bacterial skin and skin structure infections)
    • HABP (Hospital-acquired bacterial pneumonia)
    • CABP (Community-acquired pneumonia)
    • cIAI (Complicated intra-abdominal infection)
    • 其他的
  • 全球抗生素抗药性市场：依病原体分类
    • E. Coli
    • K. Pneumoniae
    • P. Aeruginosa
    • S. Aureus
    • A. Baumannii
    • S. Pneumoniae
    • 其他的
  • 全球抗生素抗药性市场：按配销通路
    • 医院药房
    • 零售药房
    • 线上药房
  • 全球抗生素抗药性市场：按作用机制
    • Protein Synthesis Inhibitors
    • Cell Wall Synthesis Inhibitors
    • RNA Synthesis Inhibitors
    • DNA Synthesis Inhibitors
    • 其他的

第4章市场趋势与预测分析：按地区（2018-2030）

  • 全球抗生素抗药性市场：按地区
  • 北美抗生素抗药性市场
  • 欧洲抗生素抗药性市场
  • 亚太地区抗生素抗药性市场
  • 其他地区抗生素抗药性市场

第5章竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第6章成长机会与策略分析

  • 成长机会分析
    • 按疾病分類的全球抗生素抗药性市场成长机会
    • 病原体的全球抗生素抗药性市场成长机会
    • 按配销通路的全球抗生素抗药性市场成长机会
    • 按作用机制分類的全球抗生素抗药性市场成长机会
    • 全球抗生素抗药性市场成长机会（按地区）
  • 全球抗生素抗药性市场的新趋势
  • 战略分析
    • 新产品开发
    • 全球抗生素抗药性市场产能扩张
    • 全球抗生素抗药性市场的合併、收购和合资企业
    • 认证和许可

第7章主要企业概况

  • Melinta
  • Basilea Pharmaceutical
  • Tetraphase Pharmaceuticals
  • Theravance Biopharma
  • WOCKHARDT
简介目录

Antibiotic Resistance Trends and Forecast

The future of the global antibiotic resistance market looks promising with opportunities in the hospital pharmacie, retail pharmacie and online pharmacie markets. The global antibiotic resistance market is expected to reach an estimated $12.2 billion by 2030 with a CAGR of 5.9% from 2024 to 2030. The major drivers for this market are increasing prevalence of antibiotic and growing government and non-government bodies involvement in the development of novel therapies.

A more than 150-page report is developed to help in your business decisions.

Antibiotic Resistance by Segment

The study includes a forecast for the global antibiotic resistance by disease, pathogen, distribution channel, mechanism of action, and region.

Antibiotic Resistance Market by Disease [Shipment Analysis by Value from 2018 to 2030]:

  • cUTI (Complicated Urinary Tract Infections)
  • CDI (Clostridioides Difficile Infection)
  • ABSSSI (Acute Bacterial Skin and Skin Structure Infections)
  • HABP (Hospital-Acquired Bacterial Pneumonia)
  • CABP (Community-Acquired Pneumonia)
  • cIAI (Complicated Intra-Abdominal Infection)
  • Others

Antibiotic Resistance Market by Pathogen [Shipment Analysis by Value from 2018 to 2030]:

  • E. Coli
  • K. Pneumoniae
  • P. Aeruginosa
  • S. Aureus
  • A. Baumannii
  • S. Pneumoniae
  • Others

Antibiotic Resistance Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Antibiotic Resistance Market by Mechanism of Action [Shipment Analysis by Value from 2018 to 2030]:

  • Protein Synthesis Inhibitors
  • Cell Wall Synthesis Inhibitors
  • RNA Synthesis Inhibitors
  • DNA Synthesis Inhibitors
  • Others

Antibiotic Resistance Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Antibiotic Resistance Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies antibiotic resistance companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the antibiotic resistance companies profiled in this report include-

  • Melinta
  • Basilea Pharmaceutical
  • Tetraphase Pharmaceuticals
  • Theravance Biopharma
  • WOCKHARDT

Antibiotic Resistance Market Insights

Lucintel forecasts that cUTI (complicated urinary tract infection) will remain the largest segment over the forecast period due to existence of a robust product development pipeline.

Within this market, hospital pharmacie will remain the largest segment as it plays a vital role in overseeing drug formularies, tracking resistance patterns, delivering education, and guaranteeing medication safety.

North America will remain the largest region over the forecast period due to increasing number of government programs and mandatory insurance policies in the region.

Features of the Global Antibiotic Resistance Market

Market Size Estimates: Antibiotic resistance market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Antibiotic resistance market size by various segments, such as by disease, pathogen, distribution channel, mechanism of action, and region in terms of value ($B).

Regional Analysis: Antibiotic resistance market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different diseases, pathogens, distribution channels, mechanism of actions, and regions for the antibiotic resistance market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the antibiotic resistance market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the antibiotic resistance market size?

Answer: The global antibiotic resistance market is expected to reach an estimated $12.2 billion by 2030.

Q2. What is the growth forecast for antibiotic resistance market?

Answer: The global antibiotic resistance market is expected to grow with a CAGR of 5.9% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the antibiotic resistance market?

Answer: The major drivers for this market are increasing prevalence of antibiotic and growing government and non-government bodies involvement in the development of novel therapies.

Q4. What are the major segments for antibiotic resistance market?

Answer: The future of the antibiotic resistance market looks promising with opportunities in the hospital pharmacie, retail pharmacie and online pharmacie markets.

Q5. Who are the key antibiotic resistance market companies?

Answer: Some of the key antibiotic resistance companies are as follows:

  • Melinta
  • Basilea Pharmaceutical
  • Tetraphase Pharmaceuticals
  • Theravance Biopharma
  • WOCKHARDT

Q6. Which antibiotic resistance market segment will be the largest in future?

Answer: Lucintel forecasts that cUTI (complicated urinary tract infection) will remain the largest segment over the forecast period due to existence of a robust product development pipeline.

Q7. In antibiotic resistance market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to increasing number of government programs and mandatory insurance policies in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the antibiotic resistance market by disease (cUTI (complicated urinary tract infections), CDI (clostridioides difficile infection), ABSSSI (acute bacterial skin and skin structure infections), HABP (hospital-acquired bacterial pneumonia), CABP (community-acquired pneumonia), CIAI (complicated intra-abdominal infection), and others), pathogen (e. coli, k. pneumoniae, p. aeruginosa, s. aureus, a. baumannii, s. pneumoniae, and others), distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies), mechanism of action (protein synthesis inhibitors, cell wall synthesis inhibitors, rna synthesis inhibitors, dna synthesis inhibitors, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Antibiotic Resistance Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Antibiotic Resistance Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Antibiotic Resistance Market by Disease
    • 3.3.1: cUTI (Complicated Urinary Tract Infections)
    • 3.3.2: CDI (Clostridioides difficile Infection)
    • 3.3.3: ABSSSI (Acute bacterial skin and skin structure infections)
    • 3.3.4: HABP (Hospital-acquired bacterial pneumonia)
    • 3.3.5: CABP (Community-acquired pneumonia)
    • 3.3.6: cIAI (Complicated intra-abdominal infection)
    • 3.3.7: Others
  • 3.4: Global Antibiotic Resistance Market by Pathogen
    • 3.4.1: E. coli
    • 3.4.2: K. pneumoniae
    • 3.4.3: P. aeruginosa
    • 3.4.4: S. aureus
    • 3.4.5: A. baumannii
    • 3.4.6: S. pneumoniae
    • 3.4.7: Others
  • 3.5: Global Antibiotic Resistance Market by Distribution Channel
    • 3.5.1: Hospital Pharmacies
    • 3.5.2: Retail Pharmacies
    • 3.5.3: Online Pharmacies
  • 3.6: Global Antibiotic Resistance Market by Mechanism of Action
    • 3.6.1: Protein Synthesis Inhibitors
    • 3.6.2: Cell Wall Synthesis Inhibitors
    • 3.6.3: RNA Synthesis Inhibitors
    • 3.6.4: DNA Synthesis Inhibitors
    • 3.6.5: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Antibiotic Resistance Market by Region
  • 4.2: North American Antibiotic Resistance Market
    • 4.2.2: North American Antibiotic Resistance Market by Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies
  • 4.3: European Antibiotic Resistance Market
    • 4.3.1: European Antibiotic Resistance Market by Disease: cUTI (Complicated Urinary Tract Infections), CDI (Clostridioides difficile Infection), ABSSSI (Acute bacterial skin and skin structure infections), HABP (Hospital-acquired bacterial pneumonia), CABP (Community-acquired pneumonia), cIAI (Complicated intra-abdominal infection), and Others
    • 4.3.2: European Antibiotic Resistance Market by Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies
  • 4.4: APAC Antibiotic Resistance Market
    • 4.4.1: APAC Antibiotic Resistance Market by Disease: cUTI (Complicated Urinary Tract Infections), CDI (Clostridioides difficile Infection), ABSSSI (Acute bacterial skin and skin structure infections), HABP (Hospital-acquired bacterial pneumonia), CABP (Community-acquired pneumonia), cIAI (Complicated intra-abdominal infection), and Others
    • 4.4.2: APAC Antibiotic Resistance Market by Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies
  • 4.5: ROW Antibiotic Resistance Market
    • 4.5.1: ROW Antibiotic Resistance Market by Disease: cUTI (Complicated Urinary Tract Infections), CDI (Clostridioides difficile Infection), ABSSSI (Acute bacterial skin and skin structure infections), HABP (Hospital-acquired bacterial pneumonia), CABP (Community-acquired pneumonia), cIAI (Complicated intra-abdominal infection), and Others
    • 4.5.2: ROW Antibiotic Resistance Market by Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Antibiotic Resistance Market by Disease
    • 6.1.2: Growth Opportunities for the Global Antibiotic Resistance Market by Pathogen
    • 6.1.3: Growth Opportunities for the Global Antibiotic Resistance Market by Distribution Channel
    • 6.1.4: Growth Opportunities for the Global Antibiotic Resistance Market by Mechanism of Action
    • 6.1.5: Growth Opportunities for the Global Antibiotic Resistance Market by Region
  • 6.2: Emerging Trends in the Global Antibiotic Resistance Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Antibiotic Resistance Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Antibiotic Resistance Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Melinta
  • 7.2: Basilea Pharmaceutical
  • 7.3: Tetraphase Pharmaceuticals
  • 7.4: Theravance Biopharma
  • 7.5: WOCKHARDT